Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,2R)-2-[4'-[(phenylcarbamoyl)amino][1,1'-biphenyl]-4-carbonyl]cyclopentane-1-carboxylic acid
-
(2S)-1-(3-[[(2S)-1-ethoxy-4-phenylbutan-2-yl]sulfamoyl]anilino)-4-methyl-1-oxopentan-2-yl 2,2-dimethylpropanoate
-
-
(2S)-1-[(1-[[(1S)-1-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-3-phenylpropyl]carbamoyl]cyclopentyl)amino]-4-methyl-1-oxopentan-2-yl 2,2-dimethylpropanoate
-
-
(4-[4-[4-(2-amino-5-chlorobenzamido)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexyl)acetic acid
-
(4-[4-[4-(3-chlorobenzamido)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexyl)acetic acid
-
(4-[4-[4-(5-chloro-2-nitrobenzamido)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexyl)acetic acid
-
(4-[4-[4-([[2-fluoro-5-(trifluoromethyl)phenyl]carbamoyl]amino)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexyl)acetic acid
-
(4S,7R)-4-(5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-2,2-dimethyl-4,7-bis[(4E)-4-methyl-5-[(2R)-4-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]pent-4-en-1-yl]-4,5,6,7-tetrahydro-1-benzofuran-3(2H)-one
89.23% inhibition
(trans-4-(4-[(5-benzyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
-
inhibitor displays good metabolic stability and high intestinal permeability values
(trans-4-(4-[(5-cyclopentylethyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
-
-
(trans-4-(4-[(5-cyclopentylmethyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
-
-
(trans-4-(4-[(5-[1-fluorobenzyl]-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
-
inhibitor displays good metabolic stability and high intestinal permeability values
(trans-4-(4-[(5-[2-chlorobenzyl]-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
-
inhibitor displays good metabolic stability and high intestinal permeability values
(trans-4-(4-[(5-[2-fluorobenzyl]-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
-
inhibitor displays good metabolic stability and high intestinal permeability values
(trans-4-[4-[(3-benzyl-1,2,4-oxadiazol-5-yl)carbamoyl]phenyl]cyclohexyl)acetic acid
-
-
(trans-4-[4-[(5-benzyl-1,2,4-oxadiazol-3-yl)carbamoyl]phenyl]cyclohexyl)acetic acid
-
-
(trans-4-[4-[(5-benzyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl]cyclohexyl)acetic acid
-
-
1-O-Hexadecyl-2-oleoyl-sn-glycerol
-
competitive
3,5-dimethyl-6-([(6E)-6-methyl-7-[(2S)-4-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]hept-6-en-1-yl]oxy)pyrazine-2-carboxamide
-
3-(4-[4-[4-(3-chlorobenzamido)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexyl)propanoic acid
-
3-oxoolean-12-en-27-oic acid
-
the compound exhibits strong inhibition efficacy towards diacylglycerol acyltransferases 1 and 2, and acts competitively against oleoyl-CoA in vitro
3alpha-hydroxyolean-12-en-27-oic acid
-
-
3beta-hydroxyolean-12-en-27-oic acid
-
-
4-amino-6-[(4E)-4-methyl-5-[(2R)-4-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]pent-4-en-2-yn-1-yl]-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one
-
4-amino-6-[(4E)-4-methyl-5-[(2S)-4-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]pent-4-en-2-yn-1-yl]-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one
-
4-[(4-chloro-3-fluorophenyl)methyl]-N-[2-(3,4-diethoxyphenyl)ethyl]-4H-thieno[3,2-b]pyrrole-5-carboxamide
-
EC value is 0.000009 mM
4-[4-(4-[[2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carbonyl]amino]phenyl)piperidine-1-carbonyl]cyclohexane-1-carboxylic acid
-
4-[4-[4-(3-chlorobenzamido)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexane-1-carboxylic acid
-
7beta-(3-ethyl-cis-crotonoyloxy)-1alpha-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranone
-
-
8-angeloyloxy-3,4-epoxy-bisabola-7(14),10-dien-2-one
-
-
aceriphyllic acid A
-
the compound exhibits strong inhibition efficacy towards diacylglycerol acyltransferases 1 and 2, and acts competitively against oleoyl-CoA in vitro
betulinic acid
-
a lupane-type triterpenoid, isolated from methanolic extracts of Alnus hirsuta, inhibition of Hep-G2 cell triacyglycerol biosynthesis
cis-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate
-
cis-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetic acid
-
cis-4-(4-[[5-(cyclopentylamino)-1,3,4-thiadiazol-2-yl]carbamoyl]phenoxy)cyclohexane-1-carboxylic acid
-
-
cis-4-([5-[(5-benzyl-1,3,4-thiadiazol-2-yl)carbamoyl]pyridin-2-yl]oxy)cyclohexane-1-carboxylic acid
-
-
cis-4-[4-([3-[(3,5-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]carbamoyl)phenoxy]cyclohexane-1-carboxylic acid
-
-
cis-4-[4-([5-[(3,5-difluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenoxy]cyclohexane-1-carboxylic acid
-
-
cis-4-[4-([5-[(cyclopentyloxy)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenoxy]cyclohexane-1-carboxylic acid
-
-
cis-4-[4-[(3-benzyl-1,2,4-oxadiazol-5-yl)carbamoyl]phenoxy]cyclohexane-1-carboxylic acid
-
-
cis-4-[4-[(5-anilino-1,3,4-thiadiazol-2-yl)carbamoyl]phenoxy]cyclohexane-1-carboxylic acid
-
-
cis-4-[4-[(5-benzyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenoxy]cyclohexane-1-carboxylic acid
-
-
cis-4-[[5-([5-[(3-chlorophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)pyridin-2-yl]oxy]cyclohexane-1-carboxylic acid
-
-
ethyl 1-(1-[[(2-chlorophenyl)carbamoyl]amino]cyclohexane-1-carbonyl)piperidine-4-carboxylate
-
EC value is 0.0015 mM
ethyl 1-[N-[(2,4-dichlorophenyl)carbamoyl]-2-methylalanyl]piperidine-4-carboxylate
-
EC value is 0.00025 mM
methyl 1-benzyl-3-[(furan-3-carbonyl)amino]-5-[(2-methylbutyl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
-
-
methyl 1-benzyl-3-[(furan-3-carbonyl)amino]-5-[[(thiophen-3-yl)methyl]amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
-
-
methyl 2-(4-(4-(4-((tert-butoxycarbonyl)amino)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohex-3-en-1-yl)acetate
-
methyl 2-(4-(4-(4-((tert-butoxycarbonyl)amino)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl) acetate
-
methyl 2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate
-
methyl 2-(4-(4-(4-aminophenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate
-
methyl 3-benzamido-1-[(furan-2-yl)methyl]-5-[(2-methylbutyl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
-
-
methyl 3-[(furan-2-carbonyl)amino]-1-(3-methylbutyl)-5-[(pentan-3-yl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
-
-
methyl 3-[(furan-3-carbonyl)amino]-1-(2-methylpropyl)-5-[(pentan-3-yl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
-
-
methyl 5-[(2,3-dihydro-1H-inden-2-yl)amino]-3-[(furan-3-carbonyl)amino]-1-(2-methylpropyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
-
-
methyl 5-[[(4-acetamidophenyl)methyl]amino]-1-benzyl-3-[(furan-3-carbonyl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
-
-
methyl 5-[[(furan-3-yl)methyl]amino]-1-(2-methylpropyl)-3-(2-phenylacetamido)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
-
-
methyl cis-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate
-
methyl trans-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate
-
N-(1-[[5-tert-butyl-1-(4-fluorophenyl)-1H-1,2,4-triazol-3-yl]amino]-2-methyl-1-oxopropan-2-yl)-4-fluorobenzamide
-
-
N-(4,5-dihydronaphtho[1,2-d]thiazol-2-yl)-2-(3,4-dimethoxy phenyl)acetamide
selective inhibitor of isoform DGAT2 when used at low concentrations; selective inhibitor of isoform DGAT2 when used at low concentrations
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-(trans-4-carbamoylcyclohexyl)benzamide
-
-
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-(trans-4-[[2-(dimethylamino)ethyl]carbamoyl]cyclohexyl)benzamide
-
-
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-(trans-4-[[2-(morpholin-4-yl)ethyl]carbamoyl]cyclohexyl)benzamide
-
-
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-[trans-4-[(2,3-dihydroxypropyl)carbamoyl]cyclohexyl]benzamide
-
-
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-[trans-4-[(2-hydroxy-2-methylpropyl)carbamoyl]cyclohexyl]benzamide
-
-
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-[trans-4-[(2-methoxyethyl)carbamoyl]cyclohexyl]benzamide
-
-
N-[(2S)-1-ethoxy-4-phenylbutan-2-yl]-1-[2-(tricyclo[3.3.1.1~3,7~]decan-2-yl)acetamido]cyclopentane-1-carboxamide
-
-
N-[1,5-bis(4-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-methyl-N~2~-[1-(trifluoromethyl)cyclopropane-1-carbonyl]alaninamide
-
-
N-[1-(3,5-dimethylphenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl]-1,2,3-thiadiazole-4-carboxamide
-
EC value is 0.10 mM
N-[1-(4-fluoro-2-methylphenyl)-5-(4-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-methyl-N~2~-[1-(trifluoromethyl)cyclopropane-1-carbonyl]alaninamide
-
-
N-[1-(4-fluorophenyl)-5-[2-(4-fluorophenyl)propan-2-yl]-1H-1,2,4-triazol-3-yl]-2-methyl-N~2~-[1-(trifluoromethyl)cyclopropane-1-carbonyl]alaninamide
-
-
N-[1-(4-hydroxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl]pyridine-2-carboxamide
-
EC value is 0.00000034 mM
N-[2-(3,4-diethoxyphenyl)ethyl]-4-methyl-4H-thieno[3,2-b]pyrrole-5-carboxamide
-
EC value is 0.011 mM
N-[5-tert-butyl-1-(4-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-methyl-N~2~-(1-methylcyclopropane-1-carbonyl)alaninamide
-
-
N-[5-tert-butyl-1-(4-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-methyl-N~2~-[1-(trifluoromethyl)cyclopropane-1-carbonyl]alaninamide
-
-
oleate
-
noncompetitive inhibition, IC50: 0.0545 mM
tert-butyl (2S)-2-[[1-([(2S)-2-[(2,2-dimethylpropanoyl)oxy]-4-methylpentanoyl]amino)cyclopentane-1-carbonyl]amino]-4-phenylbutanoate
-
-
tert-butyl (4-(7-bromothieno[3,2-d]pyrimidin-4-yl)phenyl)carbamate
-
trans-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate
-
trans-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetic acid
-
trans-4-[4-([5-[(3,5-difluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenoxy]cyclohexane-1-carboxylic acid
-
-
trans-4-[4-[(5-benzyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenoxy]cyclohexane-1-carboxylic acid
-
-
XP620
-
dihydrothiopyrancarboxamide
[(1r,4r)-4-(4-[[5-(3,4-difluoroanilino)-1,3,4-oxadiazole-2-carbonyl]amino]phenyl)cyclohexyl]acetic acid
-
[(1r,4r)-4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexyl]acetic acid
-
[(1r,4r)-4-[4-(5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl)phenyl]cyclohexyl]acetic acid
-
[(1r,4r)-4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid
89.32% inhibition
[4-(4-[4-[(naphthalene-2-carbonyl)amino]phenyl]thieno[3,2-d]pyrimidin-7-yl)cyclohexyl]acetic acid
-
[4-[4-(4-[[(3-chlorophenyl)carbamoyl]amino]phenyl)thieno[3,2-d]pyrimidin-7-yl]cyclohexyl]acetic acid
-
[4-[4-(4-[[(4-chloropyridin-2-yl)carbamoyl]amino]phenyl)thieno[3,2-d]pyrimidin-7-yl]cyclohexyl]acetic acid
-
[4-[4-(4-[[(5-bromopyridin-3-yl)carbamoyl]amino]phenyl)thieno[3,2-d]pyrimidin-7-yl]cyclohexyl]acetic acid
-
[4-[4-(4-[[2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carbonyl]amino]phenyl)thieno[3,2-d]pyrimidin-7-yl]cyclohexyl]acetic acid
-
[4-[4-(4-[[6-(trifluoromethyl)pyridine-3-carbonyl]amino]phenyl)thieno[3,2-d]pyrimidin-7-yl]cyclohexyl]acetic acid
-
[trans-4-(4-[[5-(2-cyclopentylethyl)-1,3,4-thiadiazol-2-yl]carbamoyl]phenyl)cyclohexyl]acetic acid
-
-
[trans-4-[4-([5-[(3,5-difluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
-
-
[trans-4-[4-([5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
-
-
[trans-4-[4-([5-[(4-fluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
-
-
[trans-4-[4-([5-[(cyclopentyloxy)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
-
-
[trans-4-[4-([5-[2-(oxolan-2-yl)ethyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
-
-
[trans-4-[4-([5-[2-(oxolan-3-yl)ethyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
-
-
MgCl2
-
20 mM
additional information
design and synthesis of diacylglycerol acyltransferase 1 inhibitors based on aphadilactone C. The lactone group of aphadilactone C is introduced into the [(1r,4r)-4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexyl]acetic acid and [(1r,4r)-4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid (which have entered into clinical research) to verify whether the lactone in aphadilactone C plays the same role as carboxylic group in [(1r,4r)-4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexyl]acetic acid and [(1r,4r)-4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid. The final in vitro assay shows that the synthesized compounds have not the inhibition activity to DGAT1. This might suggest that the inhibition mechanism of aphadilactone C is not the same as of [(1r,4r)-4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexyl]acetic acid and [(1r,4r)-4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid. No inhibition by 3,5-dimethyl-6-[(1E)-1-[(2S)-4-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]prop-1-en-2-yl]pyrazine-2-carboxamide
-
additional information
-
high-throughput screening for enzyme inhibitors, quantitative-high throughput image-based assay, overview. The activity of the identified lipid storage inhibitors is evolutionary conserved. Three scaffolds: structures are characterized by a tetrahydroindazole (CT1), thienopyrrole (CT2) or arylureido (CT3) core, phenotypic analysis of thienopyrrole (CT2) treated cells
-
additional information
a series of thieno[3,2-d]pyrimidine derivatives are synthesized and their inhibitory effects against diacylglycerol acyltransferase 1 (DGAT-1) are assessed
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adrenocortical Carcinoma
Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics.
Alopecia
Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice.
Alopecia
Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse.
Alopecia
Retinol Esterification by DGAT1 Is Essential for Retinoid Homeostasis in Murine Skin.
Arthritis
Arthritis severity locus Cia4 is an early regulator of IL-6, IL-1?, and NF-?B activators' expression in pristane-induced arthritis.
Atherosclerosis
Intestine-specific DGAT1 deficiency improves atherosclerosis in apolipoprotein E knockout mice by reducing systemic cholesterol burden.
Atherosclerosis
Lack of acyl-CoA:diacylglycerol acyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice.
Atherosclerosis
Potential therapeutics for obesity and atherosclerosis: inhibitors of neutral lipid metabolism from microorganisms.
Atherosclerosis
Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium.
Brain Neoplasms
DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy.
Carcinoma, Hepatocellular
CTRP12 inhibits triglyceride synthesis and export in hepatocytes by suppressing HNF-4? and DGAT2 expression.
Carcinoma, Hepatocellular
Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression.
Carcinoma, Hepatocellular
Diacylglycerol acyltransferase-2 (DGAT2) and monoacylglycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis.
Carcinoma, Hepatocellular
Overexpression of human diacylglycerol acyltransferase 1, acyl-coa:cholesterol acyltransferase 1, or acyl-CoA:cholesterol acyltransferase 2 stimulates secretion of apolipoprotein B-containing lipoproteins in McA-RH7777 cells.
Carcinoma, Hepatocellular
Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase.
Carcinoma, Hepatocellular
The ménage à trois of autophagy, lipid droplets and liver disease.
Carcinoma, Hepatocellular
The Role of Bone Morphogenetic Protein Signaling in Non-Alcoholic Fatty Liver Disease.
Carcinoma, Hepatocellular
Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
Cardiomegaly
Reduction of Rat Cardiac Hypertrophy by Osthol is Related to Regulation of Cardiac Oxidative Stress and Lipid Metabolism.
Cardiomyopathies
A murine model of isolated cardiac steatosis leads to cardiomyopathy.
Cardiomyopathies
Diacylglycerol acyl transferase 1 overexpression detoxifies cardiac lipids in PPAR? transgenic mice.
Cardiomyopathies
Inborn errors of cytoplasmic triglyceride metabolism.
ceramidase deficiency
Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner.
Charcot-Marie-Tooth Disease
DGAT2 Mutation in a Family with Autosomal Dominant Early-Onset Axonal Charcot-Marie-Tooth Disease.
Citrullinemia
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
coagulation factor xia deficiency
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
COVID-19
Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators.
Dehydration
Stability of diacylglycerol acyltransferase in dehydrated bovine muscle tissue.
Dehydration
The important role of epidermal triacylglycerol metabolism for maintenance of the skin permeability barrier function.
Dermatitis, Phototoxic
Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor.
Dermatitis, Phototoxic
The DGAT1 inhibitor pradigastat does not induce photosensitivity in healthy human subjects: a randomized controlled trial using three defined sunlight exposure conditions.
Diabetes Mellitus
DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus.
Diabetes Mellitus
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Diabetes Mellitus
RNA interference-mediated knockdown of DGAT1 decreases triglyceride content of bovine mammary epithelial cell line.
Diabetes Mellitus
Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase.
Diabetes Mellitus
Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance.
Diabetes Mellitus, Type 2
A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism.
Diabetes Mellitus, Type 2
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.
Diabetes Mellitus, Type 2
DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Diabetes Mellitus, Type 2
Diacylglycerol acyltransferase-inhibitory compounds from Erythrina senegalensis.
Diabetes Mellitus, Type 2
Effects of Morus root bark extract and active constituents on blood lipids in hyperlipidemia rats.
Diabetes Mellitus, Type 2
Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.
Diabetes Mellitus, Type 2
Inhibition of diacylglycerol acyltransferase by alkamides isolated from the fruits of Piper longum and Piper nigrum.
Diabetes Mellitus, Type 2
Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice.
Diabetes Mellitus, Type 2
Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the roots of licorice.
Diabetes Mellitus, Type 2
Isolation of Diacyl Glycerol Acyl Transferase (DGAT) Inhibitors from Pachydictyon coriaceum.
Diabetes Mellitus, Type 2
Prolonged silencing of diacylglycerol acyltransferase-1 induces a dedifferentiated phenotype in human liver cells.
Diabetes Mellitus, Type 2
Proof of mechanism for the DGAT1 inhibitor AZD7687: Results from a first-time-in-human single dose study.
Diabetes Mellitus, Type 2
Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases.
Diabetes Mellitus, Type 2
Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance.
diacylglycerol o-acyltransferase deficiency
A Fluorescence-based Assay for Characterization and Quantification of Lipid Droplet Formation in Human Intestinal Organoids.
diacylglycerol o-acyltransferase deficiency
Acyl-CoA:Diacylglycerol Acyltransferase 1 Expression Level in the Hematopoietic Compartment Impacts Inflammation in the Vascular Plaques of Atherosclerotic Mice.
diacylglycerol o-acyltransferase deficiency
Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations.
diacylglycerol o-acyltransferase deficiency
Deficiency of acyl coenzyme a:diacylglycerol acyltransferase 1 increases leptin sensitivity in murine obesity models.
diacylglycerol o-acyltransferase deficiency
DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle.
diacylglycerol o-acyltransferase deficiency
DGAT1 deficiency disrupts lysosome function in enterocytes during dietary fat absorption.
diacylglycerol o-acyltransferase deficiency
DGAT1 mutations leading to delayed chronic diarrhoea: a case report.
diacylglycerol o-acyltransferase deficiency
DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women.
diacylglycerol o-acyltransferase deficiency
Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release.
diacylglycerol o-acyltransferase deficiency
Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin.
diacylglycerol o-acyltransferase deficiency
Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.
diacylglycerol o-acyltransferase deficiency
Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice.
diacylglycerol o-acyltransferase deficiency
Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1.
diacylglycerol o-acyltransferase deficiency
Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice.
diacylglycerol o-acyltransferase deficiency
Intestinal DGAT1 deficiency markedly reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying.
diacylglycerol o-acyltransferase deficiency
Intestinal failure and aberrant lipid metabolism in patients with DGAT1 deficiency.
diacylglycerol o-acyltransferase deficiency
Intestine-specific DGAT1 deficiency improves atherosclerosis in apolipoprotein E knockout mice by reducing systemic cholesterol burden.
diacylglycerol o-acyltransferase deficiency
Lack of acyl-CoA:diacylglycerol acyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice.
diacylglycerol o-acyltransferase deficiency
Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands.
diacylglycerol o-acyltransferase deficiency
Novel role of a triglyceride-synthesizing enzyme: DGAT1 at the crossroad between triglyceride and cholesterol metabolism.
diacylglycerol o-acyltransferase deficiency
Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1.
diacylglycerol o-acyltransferase deficiency
Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat.
diacylglycerol o-acyltransferase deficiency
Palmitic Acid and DGAT1 Deficiency Enhance Osteoclastogenesis while Oleic Acid-Induced Triglyceride Formation Prevents it.
diacylglycerol o-acyltransferase deficiency
Retinol Esterification by DGAT1 Is Essential for Retinoid Homeostasis in Murine Skin.
diacylglycerol o-acyltransferase deficiency
Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1.
diacylglycerol o-acyltransferase deficiency
Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids.
diacylglycerol o-acyltransferase deficiency
Sterol and diacylglycerol acyltransferase deficiency triggers fatty acid mediated cell death.
diacylglycerol o-acyltransferase deficiency
Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance.
Dwarfism
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Dyslipidemias
A murine model of isolated cardiac steatosis leads to cardiomyopathy.
Dyslipidemias
A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism.
Dyslipidemias
A simple homogeneous scintillation proximity assay for acyl-coenzyme A:diacylglycerol acyltransferase.
Dyslipidemias
DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates.
Dyslipidemias
Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes.
Dyslipidemias
Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.
Dyslipidemias
Elevated metabolic rate and skeletal muscle oxidative metabolism contribute to the reduced susceptibility of NF-?B p50 null mice to obesity.
Dyslipidemias
Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Dyslipidemias
Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.
Dyslipidemias
Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients.
Dystocia
Deciphering signature of selection affecting beef quality traits in Angus cattle.
Encephalomyelitis
DGAT1 inhibits retinol-dependent regulatory T cell formation and mediates autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
DGAT1 inhibits retinol-dependent regulatory T cell formation and mediates autoimmune encephalomyelitis.
Escherichia coli Infections
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Factor XI Deficiency
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Farber Lipogranulomatosis
Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner.
Fatty Liver
Betaine attenuates chronic alcohol?induced fatty liver by broadly regulating hepatic lipid metabolism.
Fatty Liver
Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets.
Fatty Liver
Dietary fat composition influences tissue lipid profile and gene expression in Fischer-344 rats.
Fatty Liver
Hepatic triacylglycerol synthesis during a period of fatty liver development in sheep.
Fatty Liver
Hepatic triacylglycerol synthesizing activity during progression of alcoholic liver injury in the baboon.
Fatty Liver
Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Fatty Liver
Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease.
Fatty Liver
JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis.
Fatty Liver
Low abundance of mitofusin 2 in dairy cows with moderate fatty liver is associated with alterations in hepatic lipid metabolism.
Fatty Liver
Mangiferin treatment inhibits hepatic expression of acyl-coenzyme A:diacylglycerol acyltransferase-2 in fructose-fed spontaneously hypertensive rats: a link to amelioration of fatty liver.
Fatty Liver
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Fatty Liver
Osthole improves fat milk-induced fatty liver in rats: modulation of hepatic PPAR-alpha/gamma-mediated lipogenic gene expression.
Fatty Liver
Osthole regulates enzyme protein expression of CYP7A1 and DGAT2 via activation of PPARalpha/gamma in fat milk-induced fatty liver rats.
Fatty Liver
Perilipin 5 promotes hepatic steatosis in dairy cows through increasing lipid synthesis and decreasing very low density lipoprotein assembly.
Fatty Liver
Recent advances in pharmacotherapy for hypertriglyceridemia.
Fatty Liver
Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing.
Fatty Liver
Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
Fatty Liver
Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids.
Fatty Liver
The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans.
Fatty Liver
The ménage à trois of autophagy, lipid droplets and liver disease.
Fatty Liver
Treatment of rats with Jiangzhi Capsule improves liquid fructose-induced fatty liver: modulation of hepatic expression of SREBP-1c and DGAT-2.
Fatty Liver
[6]-gingerol dampens hepatic steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Fatty Liver, Alcoholic
Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease.
Genetic Diseases, Inborn
Deciphering signature of selection affecting beef quality traits in Angus cattle.
Glioblastoma
DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy.
Glioblastoma
Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress.
Glucose Intolerance
Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin.
Glucose Intolerance
Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.
Glucose Intolerance
Exposure to high fructose corn syrup during adolescence in the mouse alters hepatic metabolism and the microbiome in a sex-specific manner.
Glucose Intolerance
Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1.
Glucose Intolerance
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.
Glucose Intolerance
The triglyceride synthesis enzymes DGAT1 and DGAT2 have distinct and overlapping functions in adipocytes.
Heart Failure
Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure.
Hepatitis B
Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver.
Hepatitis C
Current Status of the Research and Development of Diacylglycerol O-Acyltransferase 1 (DGAT1) Inhibitors.
Hepatitis C
Diacylglycerol acyltransferase-1: a critical host factor for hepatitis C virus assembly and potential new drug target.
Hepatitis C
Diacylglycerol glycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core.
Hepatitis C
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1.
Hepatitis C
Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells.
Hepatitis C
Suppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor.
Hepatoblastoma
Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells.
Hernia, Umbilical
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Hypercholesterolemia
Novel role of a triglyceride-synthesizing enzyme: DGAT1 at the crossroad between triglyceride and cholesterol metabolism.
Hyperglycemia
A murine model of isolated cardiac steatosis leads to cardiomyopathy.
Hyperlipidemias
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Hyperlipidemias
Hepatic triacylglycerol synthesizing activity during progression of alcoholic liver injury in the baboon.
Hyperlipidemias
In vivo efficacy of acyl CoA: Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.
Hyperlipidemias
Mechanistic Characterization of Long Residence Time Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2).
Hyperlipidemias
Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight gain, hyperlipidemia, and hepatic steatosis in db/db mice.
Hyperlipidemias
Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.
Hyperlipoproteinemia Type I
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor.
Hyperlipoproteinemia Type I
Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in Humans.
Hyperlipoproteinemia Type I
Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.
Hyperlipoproteinemia Type I
Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.
Hyperlipoproteinemia Type I
Evaluation of food effect on the oral bioavailability of pradigastat, a diacylglycerol acyltransferase 1 inhibitor.
Hyperlipoproteinemia Type I
Pradigastat disposition in humans: in vivo and in vitro investigations.
Hyperlipoproteinemia Type I
Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor.
Hyperlipoproteinemia Type I
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy.
Hypertriglyceridemia
Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster.
Hypertriglyceridemia
Identification of a botanical inhibitor of intestinal diacylglyceride acyltransferase 1 activity via in vitro screening and a parallel, randomized, blinded, placebo-controlled clinical trial.
Hypertriglyceridemia
Identification of diacylglycerol acyltransferase inhibitors from Rosa centifolia petals.
Hypertriglyceridemia
Inborn errors of cytoplasmic triglyceride metabolism.
Hypertriglyceridemia
Knockdown of Acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice.
Hypertriglyceridemia
Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome.
Hypothyroidism
Comparison of triacylglycerol synthesis in rat brown and white adipocytes. Effects of hypothyroidism and streptozotocin-diabetes on enzyme activities and metabolic fluxes.
Ichthyosis
Inborn errors of cytoplasmic triglyceride metabolism.
Infections
A novel bifunctional wax ester synthase/acyl-CoA:diacylglycerol acyltransferase mediates wax ester and triacylglycerol biosynthesis in Acinetobacter calcoaceticus ADP1.
Infections
Diacylglycerol glycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core.
Infections
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Infections
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1.
Infections
Necrosis Driven Triglyceride Synthesis Primes Macrophages for Inflammation During Mycobacterium tuberculosis Infection.
Infertility
On the Role of DGAT1 in Seed Glycerolipid Metabolic Network and Critical Stages of Plant Development in Arabidopsis.
Insulin Resistance
A novel diacylglycerol acyltransferase (DGAT2) is decreased in human psoriatic skin and increased in diabetic mice.
Insulin Resistance
Abrogating Monoacylglycerol Acyltransferase Activity in Liver Improves Glucose Tolerance and Hepatic Insulin Signaling in Obese Mice.
Insulin Resistance
Analysis of Differentially Expressed Genes in Gastrocnemius Muscle between DGAT1 Transgenic Mice and Wild-Type Mice.
Insulin Resistance
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Insulin Resistance
Beyond Triglyceride Synthesis: The Dynamic Functional Roles of MGAT and DGAT Enzymes in Energy Metabolism.
Insulin Resistance
Bioactive Compounds from Lemon (Citrus limon) Extract Overcome TNF-?-Induced Insulin Resistance in Cultured Adipocytes.
Insulin Resistance
Bromodomain-containing protein 4 regulates a cascade of lipid-accumulation-related genes at the transcriptional level in the 3T3-L1 white adipocyte-like cell line.
Insulin Resistance
Decreased lipogenesis-promoting factors in adipose tissue in postmenopausal women with overweight on a Paleolithic-type diet.
Insulin Resistance
Deficiency of acyl coenzyme a:diacylglycerol acyltransferase 1 increases leptin sensitivity in murine obesity models.
Insulin Resistance
DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation.
Insulin Resistance
Discovery of a novel class of diacylglycerol acyltransferase 2 inhibitors with a 1H-pyrrolo[2,3-b]pyridine core.
Insulin Resistance
Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes.
Insulin Resistance
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.
Insulin Resistance
Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver.
Insulin Resistance
Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue.
Insulin Resistance
Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin.
Insulin Resistance
Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.
Insulin Resistance
Expression of DGAT2 in white adipose tissue is regulated by central leptin action.
Insulin Resistance
Glycerolipid acyltransferases in triglyceride metabolism and energy homeostasis-potential as drug targets.
Insulin Resistance
Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2.
Insulin Resistance
Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia.
Insulin Resistance
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Insulin Resistance
Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Insulin Resistance
Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity.
Insulin Resistance
Improved glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent on diet.
Insulin Resistance
In vivo efficacy of acyl CoA: Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.
Insulin Resistance
Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1.
Insulin Resistance
Increased lipid accumulation and insulin resistance in transgenic mice expressing DGAT2 in glycolytic (type II) muscle.
Insulin Resistance
Intestine-targeted DGAT1 inhibition improves obesity and insulin resistance without skin aberrations in mice.
Insulin Resistance
Liver fat accumulation may be dissociated from adiposity gain in ovariectomized rats.
Insulin Resistance
Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform.
Insulin Resistance
Monoacylglycerol acyltransferase 1 knockdown exacerbates hepatic ischemia-reperfusion injury in mice with hepatic steatosis.
Insulin Resistance
Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1.
Insulin Resistance
Palmitate-induced skeletal muscle insulin resistance does not require NF-kappaB activation.
Insulin Resistance
Paradoxical coupling of triglyceride synthesis and fatty acid oxidation in skeletal muscle overexpressing DGAT1.
Insulin Resistance
Paradoxical increase in TAG and DAG content parallel the insulin sensitizing effect of unilateral DGAT1 overexpression in rat skeletal muscle.
Insulin Resistance
Reduced skeletal muscle oxidative capacity and elevatedceramidebut not diacylglycerol content in severe obesity.
Insulin Resistance
Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
Insulin Resistance
Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1.
Insulin Resistance
Storing up trouble: does accumulation of intramyocellular triglyceride protect skeletal muscle from insulin resistance?
Insulin Resistance
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
Insulin Resistance
Tangduqing Granules Attenuate Insulin Resistance and Abnormal Lipid Metabolism through the Coordinated Regulation of PPAR? and DGAT2 in Type 2 Diabetic Rats.
Insulin Resistance
Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases.
Insulin Resistance
The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans.
Insulin Resistance
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.
Insulin Resistance
The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism.
Insulin Resistance
Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance.
Insulin Resistance
Whole-body Insulin Resistance in the Absence of Obesity in FVB Mice With Overexpression of Dgat1 in Adipose Tissue.
Insulin Resistance
[Effect of Jinlida on DGAT1 in Skeletal Muscle in Fat-Induced Insulin Resistance ApoE -/- Mice].
Intestinal Failure
Intestinal failure and aberrant lipid metabolism in patients with DGAT1 deficiency.
Lipid Metabolism Disorders
Tangduqing Granules Attenuate Insulin Resistance and Abnormal Lipid Metabolism through the Coordinated Regulation of PPAR? and DGAT2 in Type 2 Diabetic Rats.
Lipodystrophy
Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids.
Liver Cirrhosis
Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis.
Liver Diseases
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Liver Diseases
Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease.
Liver Diseases
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Liver Diseases
Nonalcoholic fatty liver disease: emerging mechanisms and consequences.
Liver Diseases
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Liver Diseases
Recent advances in pharmacotherapy for hypertriglyceridemia.
Liver Diseases
Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
Liver Diseases
The ménage à trois of autophagy, lipid droplets and liver disease.
Liver Diseases
Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors.
Liver Diseases
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Liver Diseases, Alcoholic
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Malnutrition
Genetic variants in DGAT1 cause diverse clinical presentations of malnutrition through a specific molecular mechanism.
Maple Syrup Urine Disease
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Mastitis
Distinguishing pleiotropy from linked QTL between milk production traits and mastitis resistance in Nordic Holstein cattle.
Mastitis
Significant genetic effects of JAK2 and DGAT1 mutations on milk fat content and mastitis resistance in Holsteins.
Metabolic Diseases
A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism.
Metabolic Diseases
ACAT-selective and Nonselective DGAT1 Inhibition: Adrenocortical Effects--A Cross-species Comparison.
Metabolic Diseases
Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid.
Metabolic Diseases
Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.
Metabolic Diseases
DGAT1 inhibitors protect pancreatic ?-cells from palmitic acid-induced apoptosis.
Metabolic Diseases
Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release.
Metabolic Diseases
Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity.
Metabolic Diseases
Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents.
Metabolic Diseases
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).
Metabolic Diseases
Patent landscape for discovery of promising acyltransferase DGAT and MGAT inhibitors.
Metabolic Diseases
Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse.
Metabolic Diseases
Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile.
Metabolic Diseases
Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases.
Metabolic Diseases
Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors.
Metabolic Diseases
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
Metabolic Syndrome
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Metabolic Syndrome
Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.
Metabolic Syndrome
Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes.
Metabolic Syndrome
Novel acyl coenzyme A: diacylglycerol acyltransferase 1 inhibitors-synthesis and biological activities of N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides.
Metabolic Syndrome
Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase.
Metabolic Syndrome
SIRT6 protects against pathological damage caused by diet-induced obesity.
Muscular Diseases
Inborn errors of cytoplasmic triglyceride metabolism.
Neoplasm Metastasis
Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis.
Neoplasms
Activation of diacylglycerol O-acyltransferase 1 gene results in increased tumor necrosis factor-alpha gene expression in 3T3-L1 adipocytes.
Neoplasms
Cardiac metabolism, inflammation, and peroxisome proliferator-activated receptors modulated by 1,25-dihydroxyvitamin D3 in diabetic rats.
Neoplasms
Cell-based assay of MGAT2-driven diacylglycerol synthesis for profiling inhibitors: use of a stable isotope-labeled substrate and high-resolution LC/MS.
Neoplasms
Comprehensive Genetic Analysis of DGAT2 Mutations and Gene Expression Patterns in Human Cancers.
Neoplasms
DGAT1 Expression Promotes Ovarian Cancer Progression and Is Associated with Poor Prognosis.
Neoplasms
DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130.
Neoplasms
DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy.
Neoplasms
Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression.
Neoplasms
Direct and maternal n-3 long-chain polyunsaturated fatty acid supplementation improved triglyceridemia and glycemia through the regulation of hepatic and muscle sphingolipid synthesis in offspring hamsters fed a high-fat diet.
Neoplasms
Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.
Neoplasms
HDAC Inhibition Modulates Cardiac PPARs and Fatty Acid Metabolism in Diabetic Cardiomyopathy.
Neoplasms
Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models.
Neoplasms
Intracellular mechanisms underlying lipid accumulation (white opaque substance) in gastric epithelial neoplasms: A pilot study of expression profiles of lipid-metabolism-associated genes.
Neoplasms
Loss of ephrin B2 receptor (EPHB2) sets lipid rheostat by regulating proteins DGAT1 and ATGL inducing lipid droplet storage in prostate cancer cells.
Neoplasms
Maternal supplementation with n-3 long chain polyunsaturated fatty acids during perinatal period alleviates the metabolic syndrome disturbances in adult hamster pups fed a high-fat diet after weaning.
Neoplasms
Mining for novel candidate clock genes in the circadian regulatory network.
Neoplasms
Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
Neoplasms
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Neoplasms
Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis.
Neoplasms
Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress.
Neoplasms
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Neoplasms
Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer.
Nephritis, Interstitial
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Nephrotic Syndrome
Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome.
Neuroinflammatory Diseases
Inflammatory, regulatory, and autophagy co-expression modules and hub genes underlie the peripheral immune response to human intracerebral hemorrhage.
Non-alcoholic Fatty Liver Disease
CD36 and DGAT2 facilitate the lipid-lowering effect of chitooligosaccharides via fatty acid intake and triglyceride synthesis signaling.
Non-alcoholic Fatty Liver Disease
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice.
Non-alcoholic Fatty Liver Disease
Monoacylglycerol acyltransferase 1 knockdown exacerbates hepatic ischemia-reperfusion injury in mice with hepatic steatosis.
Non-alcoholic Fatty Liver Disease
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).
Non-alcoholic Fatty Liver Disease
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Non-alcoholic Fatty Liver Disease
Niacin increases diet-induced hepatic steatosis in B6129 mice.
Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease: emerging mechanisms and consequences.
Non-alcoholic Fatty Liver Disease
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Non-alcoholic Fatty Liver Disease
Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Recent advances in pharmacotherapy for hypertriglyceridemia.
Non-alcoholic Fatty Liver Disease
Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
Non-alcoholic Fatty Liver Disease
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
Non-alcoholic Fatty Liver Disease
Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
The effects of PCB126 on intra-hepatic mechanisms associated with non alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
The ménage à trois of autophagy, lipid droplets and liver disease.
Non-alcoholic Fatty Liver Disease
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Obesity
A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity.
Obesity
A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism.
Obesity
A simple homogeneous scintillation proximity assay for acyl-coenzyme A:diacylglycerol acyltransferase.
Obesity
Acyl-CoA:diacylglycerol acyltransferase: Molecular biology, biochemistry and biotechnology.
Obesity
Adipose tissue fatty acid storage factors: effects of depot, sex and fat cell size.
Obesity
Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity.
Obesity
An N-terminal fragment of mouse DGAT1 binds different acyl-CoAs with varying affinity.
Obesity
Analysis of energy expenditure at different ambient temperatures in mice lacking DGAT1.
Obesity
Beyond Triglyceride Synthesis: The Dynamic Functional Roles of MGAT and DGAT Enzymes in Energy Metabolism.
Obesity
Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets.
Obesity
Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations.
Obesity
Deficiency of acyl coenzyme a:diacylglycerol acyltransferase 1 increases leptin sensitivity in murine obesity models.
Obesity
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.
Obesity
Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.
Obesity
DGAT and triglyceride synthesis: a new target for obesity treatment?
Obesity
DGAT inhibitors for obesity.
Obesity
DGAT1 inhibitors as anti-obesity and anti-diabetic agents.
Obesity
DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates.
Obesity
DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus.
Obesity
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Obesity
Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release.
Obesity
Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats.
Obesity
Diacylglycerol acyltransferase-inhibitory compounds from Erythrina senegalensis.
Obesity
Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes.
Obesity
Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.
Obesity
Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model.
Obesity
Discovery of novel DGAT1 inhibitors by combination of machine learning methods, pharmacophore model and 3D-QSAR model.
Obesity
Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes.
Obesity
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.
Obesity
Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue.
Obesity
Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin.
Obesity
Elevated metabolic rate and skeletal muscle oxidative metabolism contribute to the reduced susceptibility of NF-?B p50 null mice to obesity.
Obesity
Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.
Obesity
Evolutionary view of acyl-CoA diacylglycerol acyltransferase (DGAT), a key enzyme in neutral lipid biosynthesis.
Obesity
Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
Obesity
Expression of DGAT2 in white adipose tissue is regulated by central leptin action.
Obesity
Fighting Obesity and Metabolic Disorders with DGAT-1 Inhibitors.
Obesity
Genetic interaction of DGAT2 and FAAH in the development of human obesity.
Obesity
Glycerolipid acyltransferases in triglyceride metabolism and energy homeostasis-potential as drug targets.
Obesity
Hypertrophy and hyperplasia of abdominal adipose tissues in women.
Obesity
Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.
Obesity
Improved glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent on diet.
Obesity
In silico design of diacylglycerol acyltransferase-1 (DGAT1) inhibitors based on SMILES descriptors using Monte-Carlo method.
Obesity
Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1.
Obesity
Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1.
Obesity
Inhibition of diacylglycerol acyltransferase by alkamides isolated from the fruits of Piper longum and Piper nigrum.
Obesity
Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice.
Obesity
Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the roots of licorice.
Obesity
Intestine specific expression of acyl CoA:diacylgylcerol acyltransferase 1 (DGAT1) reverses resistance to diet-induced hepatic steatosis and obesity in Dgat1-/- mice.
Obesity
Intestine-targeted DGAT1 inhibition improves obesity and insulin resistance without skin aberrations in mice.
Obesity
Isolation of Diacyl Glycerol Acyl Transferase (DGAT) Inhibitors from Pachydictyon coriaceum.
Obesity
JTP-103237, a novel monoacylglycerol acyltransferase inhibitor, modulates fat absorption and prevents diet-induced obesity.
Obesity
JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice.
Obesity
Knockdown of Acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice.
Obesity
Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform.
Obesity
Mutation screen and association studies in the diacylglycerol O-acyltransferase homolog 2 gene (DGAT2), a positional candidate gene for early onset obesity on chromosome 11q13.
Obesity
Novel acyl coenzyme A: diacylglycerol acyltransferase 1 inhibitors-synthesis and biological activities of N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides.
Obesity
Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis.
Obesity
Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1.
Obesity
Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat.
Obesity
Pathogenesis of obesity by food restriction in OLETF rats-increased intestinal monoacylglycerol acyltransferase activities may be a crucial factor.
Obesity
Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse.
Obesity
Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes.
Obesity
Potential therapeutics for obesity and atherosclerosis: inhibitors of neutral lipid metabolism from microorganisms.
Obesity
Prolonged silencing of diacylglycerol acyltransferase-1 induces a dedifferentiated phenotype in human liver cells.
Obesity
Proof of mechanism for the DGAT1 inhibitor AZD7687: Results from a first-time-in-human single dose study.
Obesity
RNA interference-mediated knockdown of DGAT1 decreases triglyceride content of bovine mammary epithelial cell line.
Obesity
Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase.
Obesity
Sex and Depot Differences in ex vivo Adipose Tissue Fatty Acid Storage and Glycerol-3-phosphate acyltransferase Activity.
Obesity
Synthesis and biological evaluation of isoxazole, oxazole, and oxadiazole containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
Obesity
Synthesis and evaluation of cyclohexane carboxylic acid head group containing isoxazole and thiazole analogs as DGAT1 inhibitors.
Obesity
Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases.
Obesity
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.
Obesity
Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors.
Obesity
Triazolo compounds useful as diacylglycerol acyltransferase1 inhibitor - WO2009126624.
Obesity
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
Obesity
Whole-body Insulin Resistance in the Absence of Obesity in FVB Mice With Overexpression of Dgat1 in Adipose Tissue.
Obesity, Abdominal
Adipose tissue diacylglycerol acyltransferase activity and blood lipoprotein triglyceride enrichment in women with abdominal obesity.
Obesity, Morbid
Reduced skeletal muscle oxidative capacity and elevatedceramidebut not diacylglycerol content in severe obesity.
Osteopetrosis
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Osteopetrosis
Diversity of copy number variation in the worldwide goat population.
Ovarian Neoplasms
DGAT1 Expression Promotes Ovarian Cancer Progression and Is Associated with Poor Prognosis.
Overweight
Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity.
Overweight
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Overweight
Identification of a botanical inhibitor of intestinal diacylglyceride acyltransferase 1 activity via in vitro screening and a parallel, randomized, blinded, placebo-controlled clinical trial.
Overweight
Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects.
Pancreatic Neoplasms
Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis.
Prostatic Neoplasms
DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130.
Prostatic Neoplasms
Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.
Prostatic Neoplasms
Loss of ephrin B2 receptor (EPHB2) sets lipid rheostat by regulating proteins DGAT1 and ATGL inducing lipid droplet storage in prostate cancer cells.
Prostatic Neoplasms
Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5.
Protein-Losing Enteropathies
Congenital Diarrhea from DGAT1 Mutation Leading to Electrolyte Derangements, Protein-Losing Enteropathy, and Rickets.
Protein-Losing Enteropathies
Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations.
Reperfusion Injury
Eicosapentaenoic acid attenuates renal lipotoxicity by restoring autophagic flux.
Reperfusion Injury
Monoacylglycerol acyltransferase 1 knockdown exacerbates hepatic ischemia-reperfusion injury in mice with hepatic steatosis.
Rickets
Congenital Diarrhea from DGAT1 Mutation Leading to Electrolyte Derangements, Protein-Losing Enteropathy, and Rickets.
Starvation
Changes in the photosynthetic apparatus and lipid droplet formation in Chlamydomonas reinhardtii under iron deficiency.
Starvation
Cloning and molecular characterization of a novel acyl-CoA: diacylglycerol acyltransferase 1-like gene (PtDGAT1) from the diatom Phaeodactylum tricornutum.
Starvation
Effect of Single and Combined Expression of Lysophosphatidic Acid Acyltransferase, Glycerol-3-Phosphate Acyltransferase, and Diacylglycerol Acyltransferase on Lipid Accumulation and Composition in Neochloris oleoabundans.
Starvation
Identification and characterization of an efficient acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) gene from the microalga Chlorella ellipsoidea.
Starvation
PHA-4/FoxA senses nucleolar stress to regulate lipid accumulation in Caenorhabditis elegans.
Starvation
Recycling the Danger via Lipid Droplet Biogenesis After Autophagy.
Starvation
The activities of lipoprotein lipase and of enzymes involved in triacylglycerol synthesis in rat adipose tissue. Effects of starvation, dietary modification and of corticotropin injection.
Starvation
The diacylglycerol acyltransferase Rv3371 of Mycobacterium tuberculosis is required for growth arrest and involved in stress-induced cell wall alterations.
Starvation
Three acyltransferases and a nitrogen responsive regulator are implicated in nitrogen starvation-induced triacylglycerol accumulation in Chlamydomonas.
Stomach Neoplasms
Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis.
Stomach Neoplasms
Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer.
Syndactyly
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Toxoplasmosis
Novel Approaches To Kill Toxoplasma gondii by Exploiting the Uncontrolled Uptake of Unsaturated Fatty Acids and Vulnerability to Lipid Storage Inhibition of the Parasite.
triacylglycerol lipase deficiency
Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands.
Tuberculosis
Comparative genomics of the dormancy regulons in mycobacteria.
Tuberculosis
Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in Mycobacterium tuberculosis under stress.
Tuberculosis
The diacylglycerol acyltransferase Rv3371 of Mycobacterium tuberculosis is required for growth arrest and involved in stress-induced cell wall alterations.
Tuberculosis
The Mycobacterium tuberculosis Ag85A is a novel diacylglycerol acyltransferase involved in lipid body formation.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.01
(2S)-1-(3-[[(2S)-1-ethoxy-4-phenylbutan-2-yl]sulfamoyl]anilino)-4-methyl-1-oxopentan-2-yl 2,2-dimethylpropanoate
Homo sapiens
-
IC50 less than 0.01 mM, at pH 7.5 and 25°C
0.000011
(2S)-1-[(1-[[(1S)-1-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-3-phenylpropyl]carbamoyl]cyclopentyl)amino]-4-methyl-1-oxopentan-2-yl 2,2-dimethylpropanoate
Homo sapiens
-
at pH 7.5 and 25°C
0.000326
(4-[4-[4-(2-amino-5-chlorobenzamido)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexyl)acetic acid
Homo sapiens
pH 7.4, 25°C, recombinant enzyme in microsomes of Spodoptera frugiperda cells
0.000276
(4-[4-[4-(3-chlorobenzamido)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexyl)acetic acid
Homo sapiens
pH 7.4, 25°C, recombinant enzyme in microsomes of Spodoptera frugiperda cells
0.001
(4-[4-[4-(5-chloro-2-nitrobenzamido)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexyl)acetic acid
Homo sapiens
above, pH 7.4, 25°C
0.000351
(4-[4-[4-([[2-fluoro-5-(trifluoromethyl)phenyl]carbamoyl]amino)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexyl)acetic acid
Homo sapiens
pH 7.4, 25°C, recombinant enzyme in microsomes of Spodoptera frugiperda cells
0.00046
(4S,7R)-4-(5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-2,2-dimethyl-4,7-bis[(4E)-4-methyl-5-[(2R)-4-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]pent-4-en-1-yl]-4,5,6,7-tetrahydro-1-benzofuran-3(2H)-one
Homo sapiens
pH 7.4, temperature not specified in the publication
0.00036
(trans-4-(4-[(5-benzyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
Homo sapiens
-
pH not specified in the publication, 25°C
0.000019
(trans-4-(4-[(5-cyclopentylethyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
Homo sapiens
-
pH not specified in the publication, 25°C
0.000024
(trans-4-(4-[(5-cyclopentylmethyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
Homo sapiens
-
pH not specified in the publication, 25°C
0.000045
(trans-4-(4-[(5-[1-fluorobenzyl]-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
Homo sapiens
-
pH not specified in the publication, 25°C
0.00003
(trans-4-(4-[(5-[2-chlorobenzyl]-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
Homo sapiens
-
pH not specified in the publication, 25°C
0.00003
(trans-4-(4-[(5-[2-fluorobenzyl]-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl)cyclohexyl)acetic acid
Homo sapiens
-
pH not specified in the publication, 25°C
0.000253
(trans-4-[4-[(3-benzyl-1,2,4-oxadiazol-5-yl)carbamoyl]phenyl]cyclohexyl)acetic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000286
(trans-4-[4-[(5-benzyl-1,2,4-oxadiazol-3-yl)carbamoyl]phenyl]cyclohexyl)acetic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000036
(trans-4-[4-[(5-benzyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenyl]cyclohexyl)acetic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000409
3-(4-[4-[4-(3-chlorobenzamido)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexyl)propanoic acid
Homo sapiens
pH 7.4, 25°C, recombinant enzyme in microsomes of Spodoptera frugiperda cells
0.001
4-[4-[4-(3-chlorobenzamido)phenyl]thieno[3,2-d]pyrimidin-7-yl]cyclohexane-1-carboxylic acid
Homo sapiens
above, pH 7.4, 25°C
0.1607
7beta-(3-ethyl-cis-crotonoyloxy)-1alpha-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranone
Homo sapiens
-
-
0.2944
8-angeloyloxy-3,4-epoxy-bisabola-7(14),10-dien-2-one
Homo sapiens
-
-
0.2
amidepsine C
Homo sapiens
-
-
0.000022
cis-4-(4-[[5-(cyclopentylamino)-1,3,4-thiadiazol-2-yl]carbamoyl]phenoxy)cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000045
cis-4-([5-[(5-benzyl-1,3,4-thiadiazol-2-yl)carbamoyl]pyridin-2-yl]oxy)cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.00012
cis-4-[4-([3-[(3,5-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]carbamoyl)phenoxy]cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000011
cis-4-[4-([5-[(3,5-difluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenoxy]cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000012
cis-4-[4-([5-[(cyclopentyloxy)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenoxy]cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000057
cis-4-[4-[(3-benzyl-1,2,4-oxadiazol-5-yl)carbamoyl]phenoxy]cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000004
cis-4-[4-[(5-anilino-1,3,4-thiadiazol-2-yl)carbamoyl]phenoxy]cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000016
cis-4-[4-[(5-benzyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenoxy]cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000055
cis-4-[[5-([5-[(3-chlorophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)pyridin-2-yl]oxy]cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.0288
kurarinone
Homo sapiens
-
-
0.0059
methyl 1-benzyl-3-[(furan-3-carbonyl)amino]-5-[(2-methylbutyl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
Homo sapiens
-
at pH 7.4 and 37°C
0.0082
methyl 1-benzyl-3-[(furan-3-carbonyl)amino]-5-[[(thiophen-3-yl)methyl]amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
Homo sapiens
-
at pH 7.4 and 37°C
0.0074
methyl 3-benzamido-1-[(furan-2-yl)methyl]-5-[(2-methylbutyl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
Homo sapiens
-
at pH 7.4 and 37°C
0.0091
methyl 3-[(furan-2-carbonyl)amino]-1-(3-methylbutyl)-5-[(pentan-3-yl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
Homo sapiens
-
at pH 7.4 and 37°C
0.0088
methyl 3-[(furan-3-carbonyl)amino]-1-(2-methylpropyl)-5-[(pentan-3-yl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
Homo sapiens
-
at pH 7.4 and 37°C
0.0072
methyl 5-[(2,3-dihydro-1H-inden-2-yl)amino]-3-[(furan-3-carbonyl)amino]-1-(2-methylpropyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
Homo sapiens
-
at pH 7.4 and 37°C
0.0295
methyl 5-[[(4-acetamidophenyl)methyl]amino]-1-benzyl-3-[(furan-3-carbonyl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
Homo sapiens
-
at pH 7.4 and 37°C
0.0192
methyl 5-[[(furan-3-yl)methyl]amino]-1-(2-methylpropyl)-3-(2-phenylacetamido)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
Homo sapiens
-
at pH 7.4 and 37°C
0.0035
N-(1-[[5-tert-butyl-1-(4-fluorophenyl)-1H-1,2,4-triazol-3-yl]amino]-2-methyl-1-oxopropan-2-yl)-4-fluorobenzamide
Homo sapiens
-
at pH 7.5 and 25°C
0.0085 - 0.0708
N-(4,5-dihydronaphtho[1,2-d]thiazol-2-yl)-2-(3,4-dimethoxy phenyl)acetamide
0.000048
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-(trans-4-carbamoylcyclohexyl)benzamide
Homo sapiens
-
at pH 7.4 and 37°C
0.000279
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-(trans-4-[[2-(dimethylamino)ethyl]carbamoyl]cyclohexyl)benzamide
Homo sapiens
-
at pH 7.4 and 37°C
0.000122
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-(trans-4-[[2-(morpholin-4-yl)ethyl]carbamoyl]cyclohexyl)benzamide
Homo sapiens
-
at pH 7.4 and 37°C
0.000081
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-[trans-4-[(2,3-dihydroxypropyl)carbamoyl]cyclohexyl]benzamide
Homo sapiens
-
at pH 7.4 and 37°C
0.000092
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-[trans-4-[(2-hydroxy-2-methylpropyl)carbamoyl]cyclohexyl]benzamide
Homo sapiens
-
at pH 7.4 and 37°C
0.000088
N-(5-benzyl-1,3,4-thiadiazol-2-yl)-4-[trans-4-[(2-methoxyethyl)carbamoyl]cyclohexyl]benzamide
Homo sapiens
-
at pH 7.4 and 37°C
0.000027
N-[(2S)-1-ethoxy-4-phenylbutan-2-yl]-1-[2-(tricyclo[3.3.1.1~3,7~]decan-2-yl)acetamido]cyclopentane-1-carboxamide
Homo sapiens
-
at pH 7.5 and 25°C
0.00076
N-[1,5-bis(4-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-methyl-N~2~-[1-(trifluoromethyl)cyclopropane-1-carbonyl]alaninamide
Homo sapiens
-
at pH 7.5 and 25°C
0.000062
N-[1-(4-fluoro-2-methylphenyl)-5-(4-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-methyl-N~2~-[1-(trifluoromethyl)cyclopropane-1-carbonyl]alaninamide
Homo sapiens
-
at pH 7.5 and 25°C
0.0014
N-[1-(4-fluorophenyl)-5-[2-(4-fluorophenyl)propan-2-yl]-1H-1,2,4-triazol-3-yl]-2-methyl-N~2~-[1-(trifluoromethyl)cyclopropane-1-carbonyl]alaninamide
Homo sapiens
-
at pH 7.5 and 25°C
0.01
N-[5-tert-butyl-1-(4-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-methyl-N~2~-(1-methylcyclopropane-1-carbonyl)alaninamide
Homo sapiens
-
IC50 less than 0.01 mM, at pH 7.5 and 25°C
0.0048
N-[5-tert-butyl-1-(4-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-methyl-N~2~-[1-(trifluoromethyl)cyclopropane-1-carbonyl]alaninamide
Homo sapiens
-
at pH 7.5 and 25°C
0.0545
oleate
Homo sapiens
-
noncompetitive inhibition, IC50: 0.0545 mM
0.03
roselipin 1a
Homo sapiens
-
0.04
roselipin 1B
Homo sapiens
-
0.045
roselipin 2A
Homo sapiens
-
0.05
roselipin 2B
Homo sapiens
-
0.000007
tert-butyl (2S)-2-[[1-([(2S)-2-[(2,2-dimethylpropanoyl)oxy]-4-methylpentanoyl]amino)cyclopentane-1-carbonyl]amino]-4-phenylbutanoate
Homo sapiens
-
at pH 7.5 and 25°C
0.00016
trans-4-[4-([5-[(3,5-difluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenoxy]cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.00028
trans-4-[4-[(5-benzyl-1,3,4-thiadiazol-2-yl)carbamoyl]phenoxy]cyclohexane-1-carboxylic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.0491
tussilagone
Homo sapiens
-
-
0.04
xanthohumol
Homo sapiens
-
0.0000166 - 0.001499
XP620
0.000019
[(1r,4r)-4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexyl]acetic acid
Homo sapiens
pH 7.4, temperature not specified in the publication
0.000157
[(1r,4r)-4-[4-(5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl)phenyl]cyclohexyl]acetic acid
Homo sapiens
pH 7.4, 25°C
0.00008
[(1r,4r)-4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid
Homo sapiens
pH 7.4, temperature not specified in the publication
0.000398
[4-(4-[4-[(naphthalene-2-carbonyl)amino]phenyl]thieno[3,2-d]pyrimidin-7-yl)cyclohexyl]acetic acid
Homo sapiens
pH 7.4, 25°C, recombinant enzyme in microsomes of Spodoptera frugiperda cells
0.000121
[4-[4-(4-[[(3-chlorophenyl)carbamoyl]amino]phenyl)thieno[3,2-d]pyrimidin-7-yl]cyclohexyl]acetic acid
Homo sapiens
pH 7.4, 25°C, recombinant enzyme in microsomes of Spodoptera frugiperda cells
1
[4-[4-(4-[[(4-chloropyridin-2-yl)carbamoyl]amino]phenyl)thieno[3,2-d]pyrimidin-7-yl]cyclohexyl]acetic acid
Homo sapiens
above, pH 7.4, 25°C
1
[4-[4-(4-[[(5-bromopyridin-3-yl)carbamoyl]amino]phenyl)thieno[3,2-d]pyrimidin-7-yl]cyclohexyl]acetic acid
Homo sapiens
above, pH 7.4, 25°C
0.000152
[4-[4-(4-[[2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carbonyl]amino]phenyl)thieno[3,2-d]pyrimidin-7-yl]cyclohexyl]acetic acid
Homo sapiens
pH 7.4, 25°C, recombinant enzyme in microsomes of Spodoptera frugiperda cells
0.001
[4-[4-(4-[[6-(trifluoromethyl)pyridine-3-carbonyl]amino]phenyl)thieno[3,2-d]pyrimidin-7-yl]cyclohexyl]acetic acid
Homo sapiens
above, pH 7.4, 25°C
0.000019
[trans-4-(4-[[5-(2-cyclopentylethyl)-1,3,4-thiadiazol-2-yl]carbamoyl]phenyl)cyclohexyl]acetic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000009
[trans-4-[4-([5-[(3,5-difluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.00139
[trans-4-[4-([5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.0006
[trans-4-[4-([5-[(4-fluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000038
[trans-4-[4-([5-[(cyclopentyloxy)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000144
[trans-4-[4-([5-[2-(oxolan-2-yl)ethyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
Homo sapiens
-
at pH 7.4 and 37°C
0.000233
[trans-4-[4-([5-[2-(oxolan-3-yl)ethyl]-1,3,4-thiadiazol-2-yl]carbamoyl)phenyl]cyclohexyl]acetic acid
Homo sapiens
-
at pH 7.4 and 37°C
additional information
amidepsine C
-
0.04
amidepsine A
Homo sapiens
-
0.07
amidepsine A
Homo sapiens
-
0.03
amidepsine B
Homo sapiens
-
0.06
amidepsine B
Homo sapiens
-
0.02
amidepsine D
Homo sapiens
-
0.03
amidepsine D
Homo sapiens
-
0.0085
N-(4,5-dihydronaphtho[1,2-d]thiazol-2-yl)-2-(3,4-dimethoxy phenyl)acetamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0708
N-(4,5-dihydronaphtho[1,2-d]thiazol-2-yl)-2-(3,4-dimethoxy phenyl)acetamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000166
XP620
Homo sapiens
-
substrate: sn-2-monooleoylglycerol
0.0000233
XP620
Homo sapiens
-
substrate: 1-hexadecanol
0.001499
XP620
Homo sapiens
-
substrate: 1,2-dioleoyl-sn-glycerol
additional information
amidepsine C
Homo sapiens
IC50 above 0.2 mM
-
additional information
amidepsine C
Homo sapiens
IC50 above 0.2 mM
-
additional information
amidepsine C
Homo sapiens
-
IC50 above 0.2 mM
-
additional information
additional information
Homo sapiens
-
IC50 value for tussilagonone above 0.5 mM
-
additional information
roselipin 1a
Homo sapiens
IC50 above 0.2 mM
additional information
roselipin 1a
Homo sapiens
IC50 above 0.2 mM
additional information
roselipin 1a
Homo sapiens
-
IC50 above 0.2 mM
additional information
roselipin 1B
Homo sapiens
IC50 above 0.2 mM
additional information
roselipin 1B
Homo sapiens
IC50 above 0.2 mM
additional information
roselipin 1B
Homo sapiens
-
IC50 above 0.2 mM
additional information
roselipin 2A
Homo sapiens
IC50 above 0.2 mM
additional information
roselipin 2A
Homo sapiens
IC50 above 0.2 mM
additional information
roselipin 2A
Homo sapiens
-
IC50 above 0.2 mM
additional information
roselipin 2B
Homo sapiens
IC50 above 0.2 mM
additional information
roselipin 2B
Homo sapiens
IC50 above 0.2 mM
additional information
roselipin 2B
Homo sapiens
-
IC50 above 0.2 mM
additional information
XP620
Homo sapiens
-
IC50 above 0.03 mM with 1,2-dioleoyl-sn-glycerol or sn-2-monooleoylglycerol as substrate
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Kawasaki, T.; Snyder, F.
Synthesis of a novel acetylated neutral lipid related to platelet-activating factor by acyl-CoA:1-O-alkyl-2-acetyl-sn-glycerol acyltransferase in HL-60 cells [published erratum appears in J Biol Chem 1988 Jul 25;263(21):10539]
J. Biol. Chem.
263
2593-2596
1988
Homo sapiens
brenda
Cases, S.; Smith, S.J.; Zheng, Y.W.; Myers, H.M.; Lear, S.R.; Sande, E.; Novak, S.; Collins, C.; Welch, C.B.; Lusis, A.J.; Erickson, S.K.; Farese, R.V., Jr.
Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis
Proc. Natl. Acad. Sci. USA
95
13018-13023
1998
Homo sapiens, Mus musculus (Q9Z2A7), Mus musculus
brenda
Cases, S.; Stone, S.J.; Zhou, P.; Yen, E.; Tow, B.; Lardizabal, K.D.; Voelker, T.; Farese, R.V., Jr.
Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members
J. Biol. Chem.
276
38870-38876
2001
Homo sapiens (Q96PD7), Homo sapiens, Mus musculus (Q9DCV3), Mus musculus
brenda
Cheng, D.; Meegalla, R.L.; He, B.; Cromley, D.A.; Billheimer, J.T.; Young, P.R.
Human acyl-CoA:diacylglycerol acyltransferase is a tetrameric protein
Biochem. J.
359
707-714
2001
Homo sapiens
brenda
Wakimoto, K.; Chiba, H.; Michibata, H.; Seishima, M.; Kawasaki, S.; Okubo, K.; Mitsui, H.; Torii, H.; Imai, Y.
A novel diacylglycerol acyltransferase (DGAT2) is decreased in human psoriatic skin and increased in diabetic mice
Biochem. Biophys. Res. Commun.
310
296-302
2003
Homo sapiens, Mus musculus
brenda
Yen, C.L.; Brown Iv, C.H.; Monetti, M.; Farese, R.V., Jr.
A human skin multifunctional O-acyltransferase that catalyzes the synthesis of acylglycerols, waxes, and retinyl esters
J. Lipid Res.
46
2388-2397
2005
Homo sapiens
brenda
Orland, M.D.; Anwar, K.; Cromley, D.; Chu, C.; Chen, L.; Billheimer, J.T.; Hussain, M.M.; Cheng, D.
Acyl coenzyme A dependent retinol esterification by acyl coenzyme A:diacylglycerol acyltransferase 1
Biochim. Biophys. Acta
1737
76-82
2005
Homo sapiens
brenda
Turkish, A.R.; Henneberry, A.L.; Cromley, D.; Padamsee, M.; Oelkers, P.; Bazzi, H.; Christiano, A.M.; Billheimer, J.T.; Sturley, S.L.
Identification of two novel human acyl-CoA wax alcohol acyltransferases: members of the diacylglycerol acyltransferase 2 (DGAT2) gene superfamily
J. Biol. Chem.
280
14755-14764
2005
Homo sapiens, Homo sapiens (Q6ZPD8), Homo sapiens (Q96PD7)
brenda
Chung, M.Y.; Rho, M.C.; Lee, S.W.; Park, H.R.; Kim, K.; Lee, I.A.; Kim, D.H.; Jeune, K.H.; Lee, H.S.; Kim, Y.K.
Inhibition of diacylglycerol acyltransferase by betulinic acid from Alnus hirsuta
Planta Med.
72
267-269
2006
Homo sapiens, Rattus norvegicus
brenda
Park, H.R.; Yoo, M.Y.; Seo, J.H.; Kim, I.S.; Kim, N.Y.; Kang, J.Y.; Cui, L.; Lee, C.S.; Lee, C.H.; Lee, H.S.
Sesquiterpenoids isolated from the flower buds of Tussilago farfara L. inhibit diacylglycerol acyltransferase
J. Agric. Food Chem.
56
10493-10497
2008
Homo sapiens, Rattus norvegicus
brenda
Inokoshi, J.; Kawamoto, K.; Takagi, Y.; Matsuhama, M.; Omura, S.; Tomoda, H.
Expression of two human acyl-CoA:diacylglycerol acyltransferase isozymes in yeast and selectivity of microbial inhibitors toward the isozymes
J. Antibiot.
62
51-54
2009
Homo sapiens (O75907), Homo sapiens (Q96PD7), Homo sapiens
brenda
Cheng, D.; Iqbal, J.; Devenny, J.; Chu, C.H.; Chen, L.; Dong, J.; Seethala, R.; Keim, W.J.; Azzara, A.V.; Lawrence, R.M.; Pelleymounter, M.A.; Hussain, M.M.
Acylation of acylglycerols by acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption
J. Biol. Chem.
283
29802-29811
2008
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Hou, X.G.; Moser, S.; Sarr, M.G.; Thompson, G.B.; Que, F.G.; Jensen, M.D.
Visceral and subcutaneous adipose tissue diacylglycerol acyltransferase activity in humans
Obesity (Silver Spring)
17
1129-1134
2009
Homo sapiens
brenda
Mougenot, P.; Namane, C.; Fett, E.; Camy, F.; Dadji-Faihun, R.; Langot, G.; Monseau, C.; Onofri, B.; Pacquet, F.; Pascal, C.; Crespin, O.; Ben-Hassine, M.; Ragot, J.L.; Van-Pham, T.; Philippo, C.; Chatelain-Egger, F.; Peron, P.; Le Bail, J.C.; Guillot, E.; Chamiot-Clerc, P.; Chabanaud, M.A.; Pruniaux, M.-P.; Schmidt, F.; Venier, O.; Nicolai, E.; Viviani, F.
Thiadiazoles as new inhibitors of diacylglycerol acyltransferase type 1
Bioorg. Med. Chem. Lett.
22
2497-2502
2012
Homo sapiens
brenda
Wurie, H.R.; Buckett, L.; Zammit, V.A.
Diacylglycerol acyltransferase 2 acts upstream of diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and de novo synthesized fatty acids in HepG2 cells
FEBS J.
279
3033-3047
2012
Homo sapiens (O75907), Homo sapiens (Q96PD7), Homo sapiens
brenda
Hiramine, Y.; Tanabe, T.
Characterization of acyl-coenzyme A:diacylglycerol acyltransferase (DGAT) enzyme of human small intestine
J. Physiol. Biochem.
67
259-264
2011
Homo sapiens
brenda
Kim, M.O.; Lee, S.; Choi, K.; Lee, S.; Kim, H.; Kang, H.; Choi, M.; Kwon, E.B.; Kang, M.J.; Kim, S.; Lee, H.J.; Lee, H.S.; Kwak, Y.S.; Cho, S.
Discovery of a novel class of diacylglycerol acyltransferase 2 inhibitors with a 1H-pyrrolo[2,3-b]pyridine core
Biol. Pharm. Bull.
37
1655-1660
2014
Homo sapiens
brenda
Nakajima, K.; April, M.; Brewer, J.T.; Daniels, T.; Forster, C.J.; Gilmore, T.A.; Jain, M.; Kanter, A.; Kwak, Y.; Li, J.; McQuire, L.; Serrano-Wu, M.H.; Streeper, R.; Szklennik, P.; Thompson, J.; Wang, B.
Discovery of diamide compounds as diacylglycerol acyltransferase 1 (DGAT1) inhibitors
Bioorg. Med. Chem. Lett.
26
1245-1248
2016
Homo sapiens
brenda
Mougenot, P.; Namane, C.; Fett, E.; Goumy, F.; Dadji-Faihun, R.; Langot, G.; Monseau, C.; Onofri, B.; Pacquet, F.; Pascal, C.; Crespin, O.; Ben-Hassine, M.; Ragot, J.L.; Van-Pham, T.; Philippo, C.; Chatelain-Egger, F.; Peron, P.; Le Bail, J.C.; Guillot, E.; Chamiot-Clerc, P.; Chabanaud, M.A.; Pruniaux, M.-P.
Synthesis and multiparametric evaluation of thiadiazoles and oxadiazoles as diacylglycerol acyltransferase type 1 inhibitors
Bioorg. Med. Chem. Lett.
26
25-32
2016
Homo sapiens
brenda
Jin, Y.; McFie, P.J.; Banman, S.L.; Brandt, C.; Stone, S.J.
Diacylglycerol acyltransferase-2 (DGAT2) and monoacylglycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis
J. Biol. Chem.
289
28237-28248
2014
Homo sapiens
brenda
Seo, J.H.; Kim, M.O.; Han, A.R.; Kwon, E.B.; Kang, M.J.; Cho, S.; Moon, D.O.; Noh, J.R.; Lee, C.H.; Kim, Y.S.; Lee, H.S.
Oleanane-type triterpenoids of Aceriphyllum rossii and their diacylglycerol acyltransferase-inhibitory activity
Planta Med.
81
228-234
2015
Homo sapiens
brenda
Li, D.; Yin, J.; Li, J.; Nan, F.
Design and synthesis of diacylglycerol acyltransferase 1 inhibitors based on Aphadilactone C
Chinese J. Org. Chem.
36
1359-1367
2016
Homo sapiens (O75907)
-
brenda
Tschapalda, K.; Zhang, Y.Q.; Liu, L.; Golovnina, K.; Schlemper, T.; Eichmann, T.O.; Lal-Nag, M.; Sreenivasan, U.; McLenithan, J.; Ziegler, S.; Sztalryd, C.; Lass, A.; Auld, D.; Oliver, B.; Waldmann, H.; Li, Z.; Shen, M.; Boxer, M.B.; Beller, M.
A class of diacylglycerol acyltransferase 1 inhibitors identified by a combination of phenotypic high-throughput screening, genomics, and genetics
EBioMedicine
8
49-59
2016
Homo sapiens
brenda
Hong, D.J.; Jung, S.H.; Kim, J.; Jung, D.; Ahn, Y.G.; Suh, K.H.; Min, K.H.
Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors
J. Enzyme Inhib. Med. Chem.
35
227-234
2020
Canis lupus familiaris (E2RDN4), Canis lupus familiaris, Homo sapiens (O75907), Rattus norvegicus (Q9ERM3), Mus musculus (Q9Z2A7), Mus musculus
brenda
2.3.1.20 diacylglycerol O-acyltransferase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
